IN8bio (NASDAQ:INAB) Price Target Cut to $6.00 by Analysts at HC Wainwright

IN8bio (NASDAQ:INAB) had its target price dropped by HC Wainwright from $8.00 to $6.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock.

IN8bio Stock Down 0.4 %

Shares of INAB stock opened at $0.23 on Friday. IN8bio has a fifty-two week low of $0.21 and a fifty-two week high of $1.74. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a market capitalization of $18.32 million, a PE ratio of -0.30 and a beta of 0.03. The stock’s 50-day simple moving average is $0.28 and its 200-day simple moving average is $0.30.

IN8bio (NASDAQ:INAB) last issued its earnings results on Thursday, March 13th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. Equities analysts expect that IN8bio will post -0.56 earnings per share for the current year.

Institutional Trading of IN8bio

A number of hedge funds have recently modified their holdings of INAB. Jane Street Group LLC boosted its stake in shares of IN8bio by 296.7% in the fourth quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock worth $30,000 after buying an additional 86,696 shares during the last quarter. Geode Capital Management LLC boosted its position in IN8bio by 56.5% during the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock worth $133,000 after purchasing an additional 185,919 shares in the last quarter. Sigma Planning Corp boosted its position in IN8bio by 42.0% during the third quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock worth $230,000 after purchasing an additional 251,600 shares in the last quarter. Alyeska Investment Group L.P. boosted its position in IN8bio by 1,064.5% during the fourth quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock worth $1,302,000 after purchasing an additional 4,628,482 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new position in IN8bio during the fourth quarter worth approximately $1,465,000. Hedge funds and other institutional investors own 92.05% of the company’s stock.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.